Spero Therapeutics (NASDAQ:SPRO) Announces Earnings Results

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) issued its earnings results on Thursday. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.29), FiscalAI reports. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%.

Spero Therapeutics Stock Performance

SPRO opened at $1.00 on Friday. The company has a market cap of $58.41 million, a PE ratio of 9.18 and a beta of 1.59. The stock has a 50-day moving average of $1.14 and a 200-day moving average of $1.92. Spero Therapeutics has a 52-week low of $0.96 and a 52-week high of $3.08.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on SPRO shares. Weiss Ratings upgraded Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Wall Street Zen downgraded Spero Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Cantor Fitzgerald began coverage on Spero Therapeutics in a report on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 price objective on the stock. Compass Point raised shares of Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Finally, HC Wainwright lifted their target price on shares of Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Monday, September 14th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Spero Therapeutics currently has an average rating of “Hold” and a consensus target price of $6.00.

Read Our Latest Analysis on SPRO

Insider Buying and Selling at Spero Therapeutics

In related news, insider Esther Rajavelu sold 40,851 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $1.04, for a total value of $42,485.04. Following the transaction, the insider directly owned 946,000 shares of the company’s stock, valued at approximately $983,840. This trade represents a 4.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.90% of the company’s stock.

About Spero Therapeutics

(Get Free Report)

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.

Featured Stories

Earnings History for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.